<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="trials. For example, novel anti-ZIKV activities of enoxacin, amodiaquine and" exact="niclosamide" post="were discovered recently using human neural progenitor cells, human"/>
 <result pre="al., 2014, Hulseberg et al., 2019, Mazzon et al., 2019)." exact="Niclosamide" post="is an orally bioavailable anthelmintic drug which inhibits the"/>
 <result pre="also known as T-705, was approved against FLUAV in Japan;" exact="cidofovir" post="is an injectable antiviral medication used as a treatment"/>
 <result pre="viruses in the picornaviridae family, including enterovirus and rhinovirus; and" exact="valacyclovir" post="is used against CMV, EBV, HBV, HSV-1, HSV-2 and"/>
 <result pre="are undergoing surveillance studies (phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe," exact="mycophenolic acid," post="nitazoxanide and rapamycin progressed to phase IV studies without"/>
 <result pre="(phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe, mycophenolic acid, nitazoxanide and" exact="rapamycin" post="progressed to phase IV studies without approvals from national"/>
 <result pre="corona- as well as some other viral infections . Moreover," exact="chloroquine" post="and remdesivir were shown to effectively inhibit SARS-CoV-2 infection"/>
 <result pre="addition, clinical investigations into the effectiveness of lopinavir, ritonavir, remdesivir," exact="hydroxychloroquine" post="and arbidol against COVID-19 have started recently (NCT04252664; NCT0425487;"/>
 <result pre="viral strains. For example, a cocktail of nitazoxanide, favipiravir, and" exact="niclosamide" post="could be developed for the treatment of viruses belonging"/>
 <result pre="the protection of patients from the secondary infections. For example," exact="azithromycin" post="could be used against FLUAV and Chlamydophila pneumoniae, Haemophilus"/>
 <result pre="its cost (Table S1). For example, the concomitant actions of" exact="ezetimibe" post="and statins could be beneficial for treatment of both"/>
 <result pre="One82013e78425 FerreiraA.C.ReisP.A.de FreitasC.S.SacramentoC.Q.Villas Boas HoelzL.BastosM.M.Beyond members of the flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob Agents Chemother632019 FinkS.L.VojtechL.WagonerJ.SlivinskiN.S.J.JacksonK.J.WangR.The antiviral"/>
 <result pre="acidic endosomes with broad antiviral effectsPLoS Pathog82012e1002976 KaoJ.C.HuangFuW.C.TsaiT.T.HoM.R.JhanM.K.ShenT.J.The antiparasitic drug" exact="niclosamide" post="inhibits dengue virus infection by interfering with endosomal acidification"/>
 <result pre="MeneghiniK.A.HamasakiD.I.The electroretinogram of the iguana and Tokay geckoVision Res719672432515613294 MontoyaM.C.KrysanD.J.Repurposing" exact="estrogen" post="receptor antagonists for the treatment of infectious diseaseMBio92018 MorrisonT.E.DiamondM.S.Animal"/>
 <result pre="Zika virusNat Commun92018209029844387 SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci Rep720174092028098253 Sarzotti-KelsoeM.BailerR.T.TurkE.LinC.L.BilskaM.GreeneK.M.Optimization and validation of"/>
 <result pre="and tagging of every replicase proteinPLoS One112016e0151616 WangY.M.LuJ.W.LinC.C.ChinY.F.WuT.Y.LinL.I.Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmissionAntiviral Res1352016819027742486"/>
</results>
